<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124081</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F351-201503</org_study_id>
    <nct_id>NCT04124081</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects</brief_title>
  <official_title>Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects(Single Center, Single Arm, Open, Self - Control)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study, by comparing the Hydronidone capsules and entecavir capsule in a single dose and
      steady-state dosing state of both the level of blood drug concentration, assess Hydronidone
      capsules and entecavir capsule for interaction。
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Actual">August 13, 2019</completion_date>
  <primary_completion_date type="Actual">June 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma drug concentration</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Compare the difference in plasma drug concentration between single drug and two drug combinations</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hydronidone</condition>
  <arm_group>
    <arm_group_label>Drug group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydronidone capsules&amp; Entecavir capsules</intervention_name>
    <description>take the Hydronidone capsule and then the entecavir capsule, and then take the last two together</description>
    <arm_group_label>Drug group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria：

          1. gender: Chinese healthy male subject;

          2. age: 18-40 years old, with a difference of no more than 10 years;

          3. weight: ≥50kg; Body mass index [= weight kg/ (height m2)] ranged from 19 to 24.

          4. the subject (or his/her partner) has no pregnancy plan during and within 6 months
             after the trial and voluntarily takes effective physical contraception and has no
             sperm donation plan;

          5. before the trial, I have had a detailed understanding of the nature, significance,
             possible benefits, possible inconveniences and potential risks of the trial, and I
             have volunteered to participate in the clinical trial. I am able to communicate well
             with the investigator, comply with the requirements of the whole study, and have
             signed a written informed consent.

        Exclusion criteria：

          1. have participated in any other clinical trials within the first three months of the
             trial;

          2. (preliminary) of any process may affect test security, or drug in the body of the
             disease, including but not limited to: heart, liver, kidney, endocrine, the digestive
             tract, immune system and respiratory system always or the existing system diseases
             (especially cardiovascular diseases including cardiovascular disease risk, any impact
             on drug absorption of gastrointestinal diseases (such as irritable bowel syndrome
             symptoms, bowel disease or inflammatory bowel disease), active pathological bleeding
             (such as peptic ulcer), urticaria, eczema, dermatitis, epilepsy, allergic rhinitis,
             asthma, etc.);

          3. (consultation) allergy: if there are two or more drugs, food allergy history
             (including experimental drugs), lactose intolerance;

          4. (consultation) any drugs that inhibit or induce drug metabolism in the liver (common
             liver enzyme inducers: barbiturates (phenobarbital is the most common), carbamazepine,
             aminoximate, griseofulvin, aminopropyl, phenytoin, gromitol, rifampin, dexamethasone;
             Common liver enzyme inhibitors: ampromazine, cimetidine, ciprofloxacin, metronidazole,
             chloramphenicol, isoniazid, sulfonamide); Or have used any medicines (including
             Chinese herbal medicines) or health supplements within 14 days prior to initial
             administration;

          5. (consultation) have special requirements on food and cannot follow a uniform diet
             (such as intolerance to standard meals) or have difficulty swallowing;

          6. (consultation) unable to tolerate venipuncture and/or having a history of blood or
             acupuncture;

          7. (consultation) patients who have been drinking excessive amounts of tea, coffee or
             caffeinated drinks (more than 8 cups a day, 1 cup =250mL) for a long time; Or taking
             any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.)
             within 48 hours before the first administration of the drug;

          8. (consultation) previous binge drinking (i.e., male drinking more than 28 units per
             week and female drinking more than 21 units per week (1 unit contains 14g alcohol,
             such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who had
             regularly consumed alcohol (more than 14 units per week) during the 6 months prior to
             the trial; Or who had taken any alcoholic product within 24 hours of initial
             administration;

          9. (consultation) those who had donated blood or suffered massive bleeding (greater than
             450 mL) within 3 months before the first administration of the study, or who planned
             to donate blood or blood components during the study period or within 3 months after
             the end of the study;

         10. (consultation) acute disease during the screening phase before study or before study
             medication;

         11. (consultation) patients who had taken food or drinks containing enzymes that can
             induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice,
             orange juice, etc., rich in flavonoids or citrus glycosides) within 24 hours before
             the first administration were studied;

         12. (consultation) those who have had surgery within three months before the screening
             period, or who are planning to have surgery during the study period, and those who
             have had surgery that will affect drug absorption, distribution, metabolism and
             excretion;

         13. (consultation) previous history of drug abuse; A history of drug abuse;

         14. (consultation) those who have smoked more than 5 cigarettes per day in the 14 days
             before screening, or who cannot stop using any tobacco products during the trial;

         15. screening for smoking or using any tobacco products up to admission;

         16. screening phase physical examination, measurement of vital signs, electrocardiogram
             examination, laboratory examination [blood routine, urine routine, blood biochemistry,
             blood coagulation function], and the investigator judged abnormal patients with
             clinical significance;

         17. those with positive nicotine test results;

         18. alcohol breath test with test results greater than 0.0mg/100ml;

         19. positive urine drug screening;

         20. hepatitis b surface antigen positive, or hepatitis c antibody positive, or syphilis
             spirochete antibody positive, or HIV antibody positive;

         21. the investigator considers that there are any circumstances that may affect the
             subject's informed consent or adherence to the study protocol, or participation in the
             study may affect the study results or their own safety.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ethics committee of drug clinical trials of huazhong university of science and technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

